{"filing":{"accession_number":"0001213900-26-090232","cik":"0001388320","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-12","primary_document":"ea0301890-8k_actinium.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea0301890-8k_actinium.htm"},"events":[{"id":28016,"run_id":25598,"accession_number":"0001213900-26-090232","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.94,"summary":"Actinium Pharmaceuticals received notice of non-compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and (iii)) on May 27, 2026, submitted a compliance plan on June 18, 2026, and on August 12, 2026 received acceptance of that plan with a plan period through November 27, 2027. The company's stock continues to trade on NYSE American subject to compliance with the plan, with explicit warning that failure to regain compliance or make progress consistent with the plan may result in delisting proceedings.","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29793,"accession_number":"0001213900-26-090232","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Actinium received notice of non-compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and (iii)) on May 27, 2026, submitted a compliance plan on June 18, 2026, and on August 12, 2026 received acceptance of that plan with a plan period through November 27, 2027. The company's stock continues to trade on NYSE American subject to compliance with the plan and other listing standards, with explicit warning that \"If the Company does not regain compliance with the applicable continued listing standards by the end of the Plan Period or does not make progress consistent with the compliance plan during the Plan Period, NYSE Regulation may initiate delisting proceedings.\" This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T21:03:32.094746+00:00","company_name":"","ticker":null,"filing_date":""},{"id":29794,"accession_number":"0001213900-26-090232","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses that NYSE Regulation has accepted Actinium's compliance plan to regain compliance with NYSE American continued listing standards, granting a plan period through November 27, 2027. The company explicitly states it is \"not currently in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide\" and its listing is being continued pursuant to an extension. This is a material delisting-risk disclosure—the company faces potential delisting if it fails to achieve compliance within the plan period, making this a critical governance and capital-markets event for investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T21:03:32.094746+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29793,"accession_number":"0001213900-26-090232","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses that Actinium received notice of non-compliance with NYSE American continued listing standards (Sections 1003(a)(ii) and (iii)) on May 27, 2026, submitted a compliance plan on June 18, 2026, and on August 12, 2026 received acceptance of that plan with a plan period through November 27, 2027. The company's stock continues to trade on NYSE American subject to compliance with the plan and other listing standards, with explicit warning that \"If the Company does not regain compliance with the applicable continued listing standards by the end of the Plan Period or does not make progress consistent with the compliance plan during the Plan Period, NYSE Regulation may initiate delisting proceedings.\" This is a classic delisting-risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T21:03:32.094746+00:00","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-08-14"},{"id":29794,"accession_number":"0001213900-26-090232","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses that NYSE Regulation has accepted Actinium's compliance plan to regain compliance with NYSE American continued listing standards, granting a plan period through November 27, 2027. The company explicitly states it is \"not currently in compliance with Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide\" and its listing is being continued pursuant to an extension. This is a material delisting-risk disclosure—the company faces potential delisting if it fails to achieve compliance within the plan period, making this a critical governance and capital-markets event for investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T21:03:32.094746+00:00","company_name":"Actinium Pharmaceuticals, Inc.","ticker":"ATNM","filing_date":"2026-08-14"}]}